Bank of Nova Scotia
RUBY

Bank of Nova Scotia’s Rubius Therapeutics, Inc RUBY Stock Holding History

Bank of Nova Scotia’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,220
Closed -$18K – 1257
2022
Q2 		$18K Buy
+21,220
New +$35.6K ﹤0.01% 1152

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bank of Nova Scotia's RUBY Position: Q3 2022 in Review

Bank of Nova Scotia sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 21,220 shares — an estimated $18K sold.

Bank of Nova Scotia first reported a position in RUBY in Q2 2022 and held it in 1 quarter. The position peaked at $18K in Q2 2022. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Bank of Nova Scotia reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Bank of Nova Scotia sold 21,220 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $18K.
  • Bank of Nova Scotia first reported a position in Rubius Therapeutics, Inc in Q2 2022 and held it in 1 quarter.
  • Bank of Nova Scotia's Rubius Therapeutics, Inc position peaked at $18K in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Bank of Nova Scotia's 13F filing for Q3 2022, filed 10 Nov 2022.